Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on January 23, 2009. The report discloses a specific corporate event regarding the exercise of unregistered equity securities that occurred between January 1, 2009, and January 23, 2009.
Key Financial Metrics
The filing details the following financial activity related to the warrant exercises:
- Shares Issued: 1,137,896 shares of common stock.
- Gross Proceeds: Approximately $2.0 million.
- Remaining Warrants: 165,045 shares remain issuable upon exercise of remaining Callable Warrants.
- Potential Remaining Proceeds: Approximately $0.3 million.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or overall liquidity for the reporting period.
Material Changes
The primary material change is the increase in outstanding common stock and cash proceeds resulting from the exercise of callable stock purchase warrants. The transaction was conducted as a private placement exempt from registration requirements under Section 4(2) of the Securities Act.
Outlook, Risks, and Unusual Items
Expiration Deadline: Any Callable Warrants not exercised prior to 5:00 PM (Pacific) on January 28, 2009, will expire.
Unusual Items: The filing notes the specific nature of the securities as "callable stock purchase warrants" and the private placement exemption status.
The filing text does not provide management commentary, forward-looking guidance, or a discussion of general risks beyond the expiration of the warrants.
Investor Verification Checklist
- Verify the final count of shares issued after the January 28, 2009, expiration deadline.
- Confirm the total cash proceeds received from the full exercise of the Callable Warrants.
- Review the company's updated capitalization table to reflect the new share count.
- Check subsequent filings for any impact on dilution or cash position.